Envafolimab: all 66 studies that test it

Page 1 of 1. Open to participants first (44), then studies with results posted, then the rest; newest registration first within each.

• A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)RecruitingNCT07852091Phase 2
• SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLCNot yet recruitingNCT07818304Phase 2
• Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC ConversionNot yet recruitingNCT07738055Not applicable
• ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus InfectionRecruitingNCT07573943Phase 4
• Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingNCT07559864Phase 2
• A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsRecruitingNCT07260305Phase 1
• A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver SpreadNot yet recruitingNCT07256223Phase 2
• Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaNot yet recruitingNCT07159191Phase 2
• Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma PatientsNot yet recruitingNCT07142863Phase 2
• Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract CancerNot yet recruitingNCT07003815Phase 2
• A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)Not yet recruitingNCT06959693Phase 2/3
• Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric CancerRecruitingNCT06791083Phase 2
• Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerRecruitingNCT06734182Phase 2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment FailureRecruitingNCT06663007Phase 1/2
• Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingNCT06656559Phase 2
• Local Injection and Systemic Therapy in the Treatment of NSCLC.Not yet recruitingNCT06618391Phase 2
• Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingNCT06498622Phase 2
• ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCRecruitingNCT06321081Phase 2
• Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal TumorsRecruitingNCT06301828Phase 2
• Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06218004Phase 2
• A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular CarcinomaNot yet recruitingNCT06143579Phase 2
• A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung CancerRecruitingNCT06108726Phase 2
• Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.RecruitingNCT06060704Phase 2
• Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBCRecruitingNCT06013943Phase 2
• Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal CancerNot yet recruitingNCT05969847Phase 2
• Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerRecruitingNCT05959356Phase 2
• Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLCNot yet recruitingNCT05910034Phase 2
• Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal AdenocarcinomaRecruitingNCT05858567Phase 2
• Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal CancerNot yet recruitingNCT05828381Phase 2
• Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical CancerNot yet recruitingNCT05799469Phase 2
• Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal AdenocarcinomaRecruitingNCT05752136Phase 3
• Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma PatientsNot yet recruitingNCT05722977Phase 2
• First-line Replacement Maintenance of Envafolimab in Advanced NSCLCNot yet recruitingNCT05465733Phase 2
• A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung CancerNot yet recruitingNCT05414630Phase 2
• Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)RecruitingNCT05410197Phase 2
• Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.RecruitingNCT05397769Phase 2
• Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced GastricNot yet recruitingNCT05387681Phase 2
• A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLCEnrolling by invitationNCT05360979Phase 2
• Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric AdenocarcinomaRecruitingNCT05237349Phase 2
• Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLCRecruitingNCT05203276Phase 2
• Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerRecruitingNCT05112991Phase 2
• Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2
• ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid TumorsRecruitingNCT04891198Phase 2
• Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06055816Phase 2
• A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue SarcomaSuspendedNCT05941325Phase 2
• Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT05552651Phase 2
• Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal CancerStatus unknownNCT05551247Phase 2
• Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung CancerStatus unknownNCT05529355Phase 2
• Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian CancerStatus unknownNCT05422183Phase 2
• To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon CancerStatus unknownNCT05335460Phase 2
• Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIVCompletedNCT05330143Phase 2
• Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic CancerStatus unknownNCT05298020Phase 2
• Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)CompletedNCT05216653Phase 2
• Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC PatientsCompletedNCT05213221Phase 2
• Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral SuppressionStatus unknownNCT05129189Phase 2
• Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.CompletedNCT05068427Phase 2
• Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLCActive, not recruitingNCT05055167Phase 2
• A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B PatientsCompletedNCT04465890Phase 2
• KN035 in Patients With Advanced Multiple Primary TumorsStatus unknownNCT04182789Phase 2
• KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast CancerStatus unknownNCT04034823Phase 2
• KN035 for dMMR/MSI-H Advanced Solid TumorsActive, not recruitingNCT03667170Phase 2
• Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTCCompletedNCT03478488Phase 3
• A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT03248843Phase 1
• Phase I Study of KN035 in Chinese Subjects With Advanced Solid TumorsCompletedNCT03101488Phase 1
• Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid TumorsCompletedNCT02827968Phase 1

← Envafolimab overview